Genetic Technologies Limited (GNTLF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -11.43 Million AUD | -2.03% |
| 2023 | -11.2 Million AUD | -148.85% |
| 2022 | -7.2 Million AUD | 47.44% |
| 2021 | -7.15 Million AUD | -16.1% |
| 2020 | -5.87 Million AUD | -1.43% |
| 2019 | -6.4 Million AUD | -0.6% |
| 2018 | -5.96 Million AUD | 21.4% |
| 2017 | -7.79 Million AUD | 10.1% |
| 2016 | -8.43 Million AUD | 7.8% |
| 2015 | -8.54 Million AUD | 14.56% |
| 2014 | -9.39 Million AUD | -14.46% |
| 2013 | -8.92 Million AUD | -97.6% |
| 2012 | -5.25 Million AUD | -542.95% |
| 2011 | 1.06 Million AUD | -84.81% |
| 2010 | -9.7 Million AUD | 344.61% |
| 2009 | -4.25 Million AUD | -145.9% |
| 2008 | 6.27 Million AUD | 1350.99% |
| 2007 | 158.62 Thousand AUD | 111.07% |
| 2006 | -4.27 Million AUD | 37.23% |
| 2005 | -6.21 Million AUD | 18.23% |
| 2004 | -7.02 Million AUD | -803.49% |
| 2003 | -841.51 Thousand AUD | 82.41% |
| 2002 | -2.68 Million AUD | -13569.88% |
| 2001 | 35.51 Thousand AUD | 101.41% |
| 2000 | -2.51 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - AUD | -30.38% |
| 2024 Q2 | -4.88 Million AUD | -100.0% |
| 2024 Q1 | -2.44 Million AUD | 42.37% |
| 2024 Q4 | -6.8 Million AUD | 0.0% |
| 2023 Q1 | -2.53 Million AUD | 35.93% |
| 2023 Q3 | -2.48 Million AUD | 50.85% |
| 2023 Q2 | -5.06 Million AUD | -100.0% |
| 2023 FY | - AUD | -148.85% |
| 2023 Q4 | -4.23 Million AUD | -70.31% |
| 2022 Q3 | -1.79 Million AUD | 62.28% |
| 2022 Q1 | -1.8 Million AUD | 53.05% |
| 2022 FY | - AUD | 47.44% |
| 2022 Q2 | -4.75 Million AUD | -163.52% |
| 2022 Q4 | -3.94 Million AUD | -120.08% |
| 2021 Q4 | -3.84 Million AUD | -115.51% |
| 2021 Q1 | -1.79 Million AUD | 54.55% |
| 2021 Q2 | -4.3 Million AUD | -139.99% |
| 2021 Q3 | -1.78 Million AUD | 58.54% |
| 2021 FY | - AUD | -16.1% |
| 2020 Q1 | -1.3 Million AUD | 60.3% |
| 2020 Q2 | -2.94 Million AUD | -126.28% |
| 2020 Q3 | -2.35 Million AUD | 20.04% |
| 2020 Q4 | -3.94 Million AUD | -67.58% |
| 2020 FY | - AUD | -1.43% |
| 2019 Q4 | -3.27 Million AUD | -73.04% |
| 2019 Q1 | -1.53 Million AUD | -8.65% |
| 2019 Q2 | -1.53 Million AUD | -0.0% |
| 2019 FY | - AUD | -0.6% |
| 2019 Q3 | -1.89 Million AUD | -23.33% |
| 2018 Q3 | -1.41 Million AUD | 13.57% |
| 2018 Q1 | -1.63 Million AUD | 11.73% |
| 2018 FY | - AUD | 21.4% |
| 2018 Q2 | -1.63 Million AUD | -0.0% |
| 2018 Q4 | -1.41 Million AUD | 0.0% |
| 2017 Q2 | -1.95 Million AUD | 0.0% |
| 2017 FY | - AUD | 10.1% |
| 2017 Q4 | -1.85 Million AUD | 0.0% |
| 2017 Q3 | -1.85 Million AUD | 5.38% |
| 2017 Q1 | -1.95 Million AUD | 7.24% |
| 2016 Q3 | -2.11 Million AUD | -8.8% |
| 2016 Q4 | -2.11 Million AUD | 0.0% |
| 2016 Q2 | -1.94 Million AUD | 0.0% |
| 2016 Q1 | -1.94 Million AUD | 5.02% |
| 2016 FY | - AUD | 7.8% |
| 2015 FY | - AUD | 14.56% |
| 2015 Q4 | -2.04 Million AUD | 0.0% |
| 2015 Q3 | -2.04 Million AUD | 26.34% |
| 2015 Q2 | -2.77 Million AUD | 0.0% |
| 2015 Q1 | -2.77 Million AUD | -17.08% |
| 2014 Q4 | -2.36 Million AUD | 0.0% |
| 2014 FY | - AUD | -14.46% |
| 2014 Q1 | -2.56 Million AUD | 3.79% |
| 2014 Q2 | -2.56 Million AUD | 0.0% |
| 2014 Q3 | -2.36 Million AUD | 7.73% |
| 2013 FY | - AUD | -97.6% |
| 2013 Q4 | -2.66 Million AUD | 0.0% |
| 2013 Q3 | -2.66 Million AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 FY | - AUD | -542.95% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | -84.81% |
| 2011 Q2 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 344.61% |
| 2009 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | -145.9% |
| 2008 FY | - AUD | 1350.99% |
| 2008 Q2 | 1.29 Million AUD | -70.8% |
| 2008 Q1 | 4.42 Million AUD | 149.16% |
| 2008 Q4 | -14.35 Million AUD | -316.43% |
| 2008 Q3 | 6.63 Million AUD | 413.69% |
| 2007 Q1 | 2.7 Million AUD | 119.52% |
| 2007 FY | - AUD | 111.07% |
| 2007 Q2 | -1.14 Million AUD | -142.4% |
| 2007 Q3 | 4.24 Million AUD | 469.2% |
| 2007 Q4 | -8.99 Million AUD | -312.04% |
| 2006 FY | - AUD | 37.23% |
| 2006 Q1 | 3.37 Million AUD | 118.48% |
| 2006 Q2 | -167.62 Thousand AUD | -104.96% |
| 2006 Q3 | 2.56 Million AUD | 1632.68% |
| 2006 Q4 | -13.87 Million AUD | -640.11% |
| 2005 Q2 | -153.78 Thousand AUD | -104.09% |
| 2005 FY | - AUD | 18.23% |
| 2005 Q1 | 3.76 Million AUD | 0.0% |
| 2005 Q3 | 3.55 Million AUD | 2409.12% |
| 2005 Q4 | -18.26 Million AUD | -614.47% |
| 2004 FY | - AUD | -803.49% |
| 2003 FY | - AUD | 82.41% |
| 2002 FY | - AUD | -13569.88% |
| 2001 FY | - AUD | 101.41% |
| 2000 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | -882.864% |
| Arrayit Corporation | -3.07 Million USD | -271.429% |
| Atlantic International Corp. | -5.38 Million USD | -112.09% |
| Biocept, Inc. | -30.24 Million USD | 62.201% |
| Bioqual, Inc. | 3.03 Million USD | 476.972% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | -1409.254% |
| DermTech, Inc. | -97.89 Million USD | 88.323% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.392% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 43.531% |
| iMD Companies, Inc. | -154.65 Thousand USD | -7290.911% |
| IDenta Corp. | 71.58 Thousand USD | 16067.577% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 397.907% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 29644.35% |
| InVitro International | 6680.00 USD | 171218.398% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | -110.278% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | -94103.964% |
| Medical Imaging Corp. | -896.74 Thousand USD | -1174.693% |
| NovelStem International Corp. | -3.78 Million USD | -201.937% |
| Optigenex Inc. | -1.18 Million USD | -863.215% |
| PharmChem, Inc. | 1.05 Million USD | 1184.703% |
| Proteome Sciences plc | -1.13 Million USD | -905.339% |
| Response Genetics, Inc | -19.66 Million USD | 41.876% |
| Rennova Health, Inc. | -234.81 Thousand USD | -4767.964% |
| RushNet, Inc. | -614.85 Thousand USD | -1759.099% |
| ScreenPro Security Inc. | -3.43 Million USD | -232.782% |
| Stella Diagnostics Inc. | -5.7 Million USD | -100.278% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | -11.3% |
| Todos Medical Ltd. | -9.39 Million USD | -21.681% |